111 related articles for article (PubMed ID: 26945543)
1. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis.
An J; Shim JH; Kim SO; Choi J; Kim SW; Lee D; Kim KM; Lim YS; Lee HC; Chung YH; Lee YS; Suh DJ
J Med Virol; 2016 Sep; 88(9):1576-86. PubMed ID: 26945543
[TBL] [Abstract][Full Text] [Related]
2. Comparison of HBV reactivation between patients with high HBV-DNA and low HBV-DNA loads undergoing PD-1 inhibitor and concurrent antiviral prophylaxis.
He MK; Peng C; Zhao Y; Liang RB; Lai ZC; Kan A; Li QJ; Wei W; Zhang YJ; Chen MS; Guo RP; Shi M
Cancer Immunol Immunother; 2021 Nov; 70(11):3207-3216. PubMed ID: 33813646
[TBL] [Abstract][Full Text] [Related]
3. Long-term comparisons of the durability of 6 months versus 12 months antiviral therapy for hepatitis B after chemotherapy cessation.
Yang SY; Hu TH; Chou YP; Kuo YH; Tsai MC; Chang KC; Yen YH; Tseng PL
J Infect Public Health; 2023 Nov; 16(11):1852-1859. PubMed ID: 37837921
[TBL] [Abstract][Full Text] [Related]
4. Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection.
Liu S; He Z; Wu W; Jin H; Cui Y
Clin Rheumatol; 2023 Sep; 42(9):2369-2376. PubMed ID: 37219751
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis B virus management to prevent reactivation after chemotherapy: a review.
Hwang JP; Vierling JM; Zelenetz AD; Lackey SC; Loomba R
Support Care Cancer; 2012 Nov; 20(11):2999-3008. PubMed ID: 22933131
[TBL] [Abstract][Full Text] [Related]
6. Low level of hepatitis B virus screening among patients receiving chemotherapy.
Wi CI; Loo NM; Larson JJ; Moynihan TJ; Madde NR; Grendahl DC; Alberts SR; Kim WR
Clin Gastroenterol Hepatol; 2015 May; 13(5):970-5; quiz e51. PubMed ID: 25460017
[TBL] [Abstract][Full Text] [Related]
7. Case reports of latent HBV hepatitis in patients after neurosurgical treatment for hypothalamic and pituitary tumors.
Niizuma K; Ogawa Y; Kogure T; Tominaga T
BMC Infect Dis; 2020 Mar; 20(1):230. PubMed ID: 32188424
[TBL] [Abstract][Full Text] [Related]
8. Clearance of HBsAg in a patient with familial multiple myeloma after a bortezomib-based regimen combined with anti-HBV drug: A case report.
Zhang X; Liang Y; Li X; Wang W; Tong J; Xu Y
Medicine (Baltimore); 2020 Oct; 99(40):e22642. PubMed ID: 33019490
[TBL] [Abstract][Full Text] [Related]
9. Association of hepatitis B virus DNA levels with efficacy and safety outcomes in patients with hepatitis B virus-associated advanced hepatocellular carcinoma receiving tyrosine kinase inhibitor plus anti-PD-1 antibody: a multicenter propensity-matched study.
Chen QJ; Lin KY; Lin ZW; Zhang B; Liu MQ; Zhang JX; Huang QZ; Lin KC; Zhang JY; Wei FQ; You PH; You S; Jiang YB; Zhang H; Cheng ZQ; Wang CR; Zeng YY
Int Immunopharmacol; 2023 Dec; 125(Pt A):111098. PubMed ID: 37925946
[TBL] [Abstract][Full Text] [Related]
10. Prediction of Clinical Relapse and HBsAg Loss After Cessation of Anti-HBV Therapy.
Liaw YF
Gastroenterology; 2024 Jun; 166(6):1193. PubMed ID: 37866763
[No Abstract] [Full Text] [Related]
11. HBV reactivation and clinical resolution in an isolated anti-HBc-positive patient during immune checkpoint inhibition.
Baumert LS; Shih AR; Chung RT
Med; 2024 Feb; 5(2):126-131.e1. PubMed ID: 38340708
[TBL] [Abstract][Full Text] [Related]
12. Optimal timing of antiviral therapy for patients with malignant tumor who presented with hepatitis B reactivation during chemotherapy and/or immunosuppressive therapy.
Zou X; Guo L; Gu Y; Yang Z; Huang P; Liu T; Zhao J; Wu G
J Cancer; 2020; 11(12):3559-3566. PubMed ID: 32284752
[No Abstract] [Full Text] [Related]
13. Risk of hepatitis B virus reactivation in people with multiple sclerosis treated with ocrelizumab: an observational study from Turkey.
Çelik M; Baba C; Irmak Ç; Özakbaş S; Avkan-Oğuz V
J Neurol; 2024 Apr; ():. PubMed ID: 38578494
[TBL] [Abstract][Full Text] [Related]
14. Late HBV reactivation after hematopoietic stem cell transplantation, despite long-term prophylaxis.
Viscovo M; Metafuni E; Giammarco S; Santopaolo F; Frioni F; Pellegrino C; Sica S; Chiusolo P; Pompili M
Eur J Clin Microbiol Infect Dis; 2023 Dec; 42(12):1543-1545. PubMed ID: 37870712
[No Abstract] [Full Text] [Related]
15. Fulminant hepatitis in a hepatitis B surface antigen-positive patient with adult T-cell leukemia-lymphoma after mogamulizumab monotherapy.
Nakashima T; Kusumoto S; Ishida T; Kato C; Hagiwara S; Narita T; Masaki A; Ito A; Ri M; Komatsu H; Inagaki H; Tanaka Y; Iida S
Hepatol Res; 2024 May; ():. PubMed ID: 38770705
[TBL] [Abstract][Full Text] [Related]
16. Screening for viral hepatitis B infection in cancer patients before receiving chemotherapy - A systematic review and meta-analysis.
Maung ST; Deepan N; Decharatanachart P; Chaiteerakij R
Asia Pac J Clin Oncol; 2024 Mar; ():. PubMed ID: 38512893
[TBL] [Abstract][Full Text] [Related]
17. A revolutionary oral HBV treatment candidate as innovative therapeutic approach warranting clinical trials.
Matsui T
J Gastroenterol; 2024 May; 59(5):434-435. PubMed ID: 38526624
[No Abstract] [Full Text] [Related]
18. HIV pre-exposure prophylaxis as an entry point to the elimination of hepatitis B virus.
Khwairakpam G; Hicks J; Pénicaud C
Lancet Gastroenterol Hepatol; 2023 Nov; 8(11):967. PubMed ID: 37689083
[No Abstract] [Full Text] [Related]
19. Association between antiviral treatments and fracture in elderly patients with HBV needs further evaluation.
Wu JL; Luo JY; Jiang ZB
J Hepatol; 2024 Mar; ():. PubMed ID: 38527526
[No Abstract] [Full Text] [Related]
20. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
Fang HW; Tseng PL; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
Virol J; 2024 Apr; 21(1):79. PubMed ID: 38570803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
